Abstract
Retinoid resistance has limited the clinical application of retinoids as differentiation-inducing and apoptosis-inducing drugs. This study was designed to investigate whether celecoxib, a selective COX-2 inhibitor, has effects on retinoid sensitivity in human colon cancer cell lines, and to determine the possible mechanism of said effects. Cell viability was measured using the MTT assay. Apoptosis was detected via Annexin-V/PI staining and the flow cytometry assay. PGE2 production was measured with the ELISA assay. The expression of RARβ was assayed via western blotting. The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Further study showed the ATRA and celecoxib combination induced greater apoptosis, but that the addition of PGE2 did not affect the enhanced growth-inhibitory and apoptosis-inducing effects of the combination. Moreover, NS398 (another selective COX-2 inhibitor) did not affect the inhibitory effects of ATRA in the two cell lines. Western blotting showed that the expression of RARβ in HT-29 cell lines was increased by celecoxib, but not by NS398, and that the addition of PGE2 did not affect the celecoxib-induced expression of the retinoic acid receptor beta. In conclusion, celecoxib increased the expression of RARβ and the level of cellular ATRA sensitivity through COX-2-independent mechanisms. This finding may provide a potential strategy for combination therapy.
[1] Weitz, J., Koch, M., Debus, J., Hohler, T., Galle, P.R. and Buchler, M.W. Colorectal cancer. Lancet 365 (2005) 153–165. http://dx.doi.org/10.1016/S0140-6736(05)17706-X10.1016/S0140-6736(05)17706-XSearch in Google Scholar
[2] Sabharwal, A. and Kerr, D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev. Anticancer Ther. 7 (2007) 477–487. http://dx.doi.org/10.1586/14737140.7.4.47710.1586/14737140.7.4.477Search in Google Scholar
[3] Gudas, L.J., Sporn, M.B. and Roberts, A.B. Cellular biology and biochemistry of the retinoids. in: The retinoids: Biology, Chemistry, and Medicine (Sporn, M.B., Roberts, A.B. and Goodman, D.S., Eds.), 2nd edition, Raven Press, New York, 1994, 443–520. Search in Google Scholar
[4] Xu, X.C. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 253 (2007) 14–24. http://dx.doi.org/10.1016/j.canlet.2006.11.01910.1016/j.canlet.2006.11.019Search in Google Scholar
[5] Lee, M.O., Han, S.Y., Jiang, S., Park, J.H. and Kim, S.J. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem. Pharmacol. 59 (2000) 485–496. http://dx.doi.org/10.1016/S0006-2952(99)00355-X10.1016/S0006-2952(99)00355-XSearch in Google Scholar
[6] van Zandwijk, N., Dalesio, O., Pastorino, U., de Vries, N. and van Tinteren, H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl. Cancer Inst. 92 (2000) 977–986. http://dx.doi.org/10.1093/jnci/92.12.97710.1093/jnci/92.12.977Search in Google Scholar PubMed
[7] Khuri, F.R., Lee, J.J., Lippman, S.M., Kim, E.S., Cooper, J.S., Benner, S.E., Winn, R., Pajak, T.F., Williams, B., Shenouda, G., Hodson, I., Fu, K., Shin, D.M., Vokes, E.E., Feng, L., Goepfert, H. and Hong, W.K. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Natl. Cancer Inst. 98 (2006) 441–450. http://dx.doi.org/10.1093/jnci/djj09110.1093/jnci/djj091Search in Google Scholar PubMed
[8] Koki, A.T., Leahy, K.M. and Masferrer, J.L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs. 8 (1999) 1623–1638. http://dx.doi.org/10.1517/13543784.8.10.162310.1517/13543784.8.10.1623Search in Google Scholar PubMed
[9] Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M. and Moher, D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med. 146 (2007) 376–389. Search in Google Scholar
[10] Simeone, A.M., Li, Y.J., Broemeling, L.D., Johnson, M.M., Tuna, M. and Tari, A.M. Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res. 64 (2004) 1224–1228. http://dx.doi.org/10.1158/0008-5472.CAN-03-218810.1158/0008-5472.CAN-03-2188Search in Google Scholar PubMed
[11] Tari, A.M., Simeone, A.M., Li, Y.J., Gutierrez-Puente, Y., Lai, S. and Symmans, W.F. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab. Invest. 85 (2005) 1357–1367. http://dx.doi.org/10.1038/labinvest.370033910.1038/labinvest.3700339Search in Google Scholar PubMed
[12] Schroeder, C.P., Kadara, H., Lotan, D., Woo, J.K., Lee, H.Y., Hong, W.K. and Lotan, R. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res. 66 (2006) 9762–9770. http://dx.doi.org/10.1158/0008-5472.CAN-05-412410.1158/0008-5472.CAN-05-4124Search in Google Scholar PubMed
[13] Li, M., Song, S., Lippman, S.M., Zhang, X.K., Liu, X., Lotan, R. and Xu, X.C. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene 21 (2002) 411–418. http://dx.doi.org/10.1038/sj.onc.120510610.1038/sj.onc.1205106Search in Google Scholar
[14] Song, S., Lippman, S.M., Zou, Y., Ye, X., Ajani, J.A. and Xu, X.C. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene 24 (2005) 8268–8276. http://dx.doi.org/10.1038/sj.onc.120899210.1038/sj.onc.1208992Search in Google Scholar
[15] Delage, B., Bairras, C., Buaud, B., Pallet, V. and Cassand, P. A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. Int. J. Cancer. 116 (2005) 839–846. http://dx.doi.org/10.1002/ijc.2110810.1002/ijc.21108Search in Google Scholar
[16] Mernitz, H., Smith, D.E., Zhu, A.X. and Wang, X.D. 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett. 244 (2006) 101–108. http://dx.doi.org/10.1016/j.canlet.2005.12.00110.1016/j.canlet.2005.12.001Search in Google Scholar
[17] Freemantle, S.J., Spinella, M.J. and Dmitrovsky, E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22 (2003) 7305–7315. http://dx.doi.org/10.1038/sj.onc.120693610.1038/sj.onc.1206936Search in Google Scholar
[18] Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S. and Kawai, S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531 (2002) 278–284. http://dx.doi.org/10.1016/S0014-5793(02)03535-410.1016/S0014-5793(02)03535-4Search in Google Scholar
[19] Williams, C.S., Watson, A.J., Sheng, H., Helou, R., Shao, J. and DuBois, R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000) 6045–6051. Search in Google Scholar
[20] Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Euchenhofer, C., Brautigam, L., Grosch, S. and Geisslinger, G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NFkappaB. FASEB J. 15 (2001) 1622–1624. Search in Google Scholar
[21] Zrieki, A., Farinotti, R. and Buyse, M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 25 (2008) 1991–2001. http://dx.doi.org/10.1007/s11095-008-9596-110.1007/s11095-008-9596-1Search in Google Scholar PubMed
[22] Sulova, Z., Macejova, D., Seres, M., Sedlak, J., Brtko, J. and Breier, A. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol. In Vitro 22 (2008) 96–105. http://dx.doi.org/10.1016/j.tiv.2007.08.01110.1016/j.tiv.2007.08.011Search in Google Scholar PubMed
[23] Soprano, D.R., Qin, P. and Soprano, K.J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24 (2004) 201–221. http://dx.doi.org/10.1146/annurev.nutr.24.012003.13240710.1146/annurev.nutr.24.012003.132407Search in Google Scholar PubMed
[24] Grosch, S., Maier, T.J., Schiffmann, S. and Geisslinger, G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736–747. http://dx.doi.org/10.1093/jnci/djj20610.1093/jnci/djj206Search in Google Scholar PubMed
[25] Maier, T.J., Schilling, K., Schmidt, R., Geisslinger, G. and Grosch, S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67 (2004) 1469–1478. http://dx.doi.org/10.1016/j.bcp.2003.12.01410.1016/j.bcp.2003.12.014Search in Google Scholar PubMed
[26] Lefebvre, B., Brand, C., Flajollet, S. and Lefebvre, P. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway. Mol. Endocrinol. 20 (2006) 2109–2121. http://dx.doi.org/10.1210/me.2005-032110.1210/me.2005-0321Search in Google Scholar PubMed
© 2010 University of Wrocław, Poland
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
